Crown BioScience
In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…
Latest
Crown BioScience
Growing the Future of Cancer Research: Inside the Promise of Organoids
In an era where precision and predictability define the future of oncology, organoid technology is emerging as a transformative tool in drug discovery. These miniature, lab-grown 3D tissues mirror real human biology more closely than traditional 2D models or even animal systems, offering researchers the potential to predict patient-specific drug responses. As organoids become more…
Crown BioScience
Shaping the Future of Cancer Care Through Immuno-Oncology
In the ever-evolving world of cancer treatment, immuno-oncology (IO) continues to stand at the forefront of innovation. With recent FDA approvals for TIL therapies and bispecific antibodies, and new developments in CAR-T technologies, the field is rapidly expanding into combination-based strategies that integrate with standard care. Researchers are also exploring how to overcome challenges posed…
Crown BioScience
Evolving Biomarkers: Charting the Future of Precision Medicine
In a rapidly shifting landscape of personalized medicine, biomarkers have become central to shaping the way drug development and clinical trials unfold. From predicting therapeutic response to identifying optimal patient populations, the complexity and scope of biomarker use has increased alongside technological advances. A key success story like the BCR-ABL biomarker in chronic myeloid leukemia…
Crown BioScience
Exploring Artificial Intelligence in Drug Discovery
Artificial intelligence is rapidly reshaping the drug discovery process, moving from augmenting research to actively driving innovation. As biotech companies face soaring R&D costs and long development cycles, AI promises a breakthrough: slashing drug development time by nearly half while improving accuracy in identifying promising compounds. With global pharmaceutical R&D spending projected to exceed $230…
Crown BioScience
Pioneering Strategies to Unlocking the Potential of KRAS
Once labeled “undruggable,” KRAS has emerged as one of oncology’s most promising—yet complex—targets. With nearly 90% of pancreatic cancers and 30-40% of lung and colorectal cancers harboring KRAS mutations, the need for effective therapies is urgent. Recent FDA approvals of KRAS G12C inhibitors have signaled a new era, but the rise of resistance and diverse…
Latest
The Power of Purpose – Leadership and Vision with Byron Sanders
Welcome to this transformative episode of the Undisputed Podcast, where your host, Ty Bledsoe, CEO of Undisputed LLC, engages in a riveting conversation with Byron Sanders, a visionary changing the landscape of community leadership and public health. A former president and renowned CEO, Byron shares his journey from humble beginnings in Southern Dallas to reshaping…
AI in Education Can Democratize Expertise—But Only If Systems Evolve
As artificial intelligence becomes increasingly embedded in our everyday lives, AI and education are becoming more tightly intertwined. Many teachers and students are experimenting with AI in education, from personalized tutoring tools to automated lesson planning. While traditional edtech tools struggled to deliver on the promise of personalized learning, today’s generative AI appears poised to…
The Future of Fiber: Strategies and Collaboration
As next-generation broadband continues to transform digital experiences across the U.S., Internet Service Providers (ISPs) are reshaping how we think about infrastructure, speed, and scalability. The industry is no longer just about faster speeds—it’s about smarter service, tailored rollouts, and future-ready networks that can meet the evolving needs of homes, businesses, and communities. In this…
The Evolution of HVAC Media Through the Eyes of Kyle Gargaro
The HVAC industry is no longer just about furnaces and air conditioners, and neither is HVAC media. It’s an ever-evolving ecosystem, shaped by technological advances, regulatory changes, and shifting workforce dynamics. With more than a century of history, publications catering to HVAC-related news, such as ACHR News, have played a crucial role in keeping…
Latest CrownCast
Crown BioScience
Inside Oncology Drug Development: Overcoming Resistance with Science
In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…
Growing the Future of Cancer Research: Inside the Promise of Organoids
In an era where precision and predictability define the future of oncology, organoid technology is emerging as a transformative tool in drug discovery. These miniature, lab-grown 3D tissues mirror real human biology more closely than traditional 2D models or even animal systems, offering researchers the potential to predict patient-specific drug responses. As organoids become more…
Shaping the Future of Cancer Care Through Immuno-Oncology
In the ever-evolving world of cancer treatment, immuno-oncology (IO) continues to stand at the forefront of innovation. With recent FDA approvals for TIL therapies and bispecific antibodies, and new developments in CAR-T technologies, the field is rapidly expanding into combination-based strategies that integrate with standard care. Researchers are also exploring how to overcome challenges posed…
Evolving Biomarkers: Charting the Future of Precision Medicine
In a rapidly shifting landscape of personalized medicine, biomarkers have become central to shaping the way drug development and clinical trials unfold. From predicting therapeutic response to identifying optimal patient populations, the complexity and scope of biomarker use has increased alongside technological advances. A key success story like the BCR-ABL biomarker in chronic myeloid leukemia…
Crown BioScience
Exploring Artificial Intelligence in Drug Discovery
Artificial intelligence is rapidly reshaping the drug discovery process, moving from augmenting research to actively driving innovation. As biotech companies face soaring R&D costs and long development cycles, AI promises a breakthrough: slashing drug development time by nearly half while improving accuracy in identifying promising compounds. With global pharmaceutical R&D spending projected to exceed $230…
Pioneering Strategies to Unlocking the Potential of KRAS
Once labeled “undruggable,” KRAS has emerged as one of oncology’s most promising—yet complex—targets. With nearly 90% of pancreatic cancers and 30-40% of lung and colorectal cancers harboring KRAS mutations, the need for effective therapies is urgent. Recent FDA approvals of KRAS G12C inhibitors have signaled a new era, but the rise of resistance and diverse…
